Novo Nordisk - Search News

The Motley Fool · 38m

Is Novo Nordisk Stock a Buy?

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity.

Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Washington Examiner on MSN · 15h

Novo Nordisk stock prices drop after Biden lists Ozempic for price negotiations

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.

Investing.com on MSN · 20h

BofA reiterates Buy on Novo Nordisk shares on performance

BofA Securities maintained a Buy rating on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) with a price target of DKK1,075.00. The firm's analyst commented on the stock's recent performance, noting a significant downturn in the second half of 2024,

TipRanks on MSN · 20h

Novo Nordisk price target lowered to $110 from $140 at Argus

Argus lowered the firm’s price target on Novo Nordisk (NVO) to $110 from $140 but keeps a Buy rating on the shares and contends that the stock’s

20hon MSN

US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

18hon MSN

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

FiercePharma21h

Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

19hon MSN

Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

17h

LVMH overtakes Novo Nordisk as Europe’s most valuable company

Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...

1d

Finally An Attractive Entry Point Into Novo Nordisk

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

1d

Novo Nordisk, other firms meet Danish PM to discuss Trump tariff threats

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...

9don MSN

Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

19h

Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks

GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along ...

13hon MSN

These Stocks Moved the Most Today: Apple, Alphabet, Qorvo, Novo Nordisk, SLB, J.B. Hunt, Rivian, and More

Stocks rallied sharply Friday and the S&P 500 was on pace for its best week since early November.These stocks were making ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results